




P. No 2999

AUTHORS

Dr. Raghu S Thota, Dr Shruthi Kamble, Dr. Jayita Deodhar

01. INTRODUCTION

Chemotherapy peripheral induced neuropathy (CIPN) is a very common complication of cancer chemotherapy with an incidence of 30-40% of patients¹. The risk is higher with cisplatin, paclitaxel, docetaxel, vincristine, oxaliplatin, and bortezomib². The extent of the neurotoxicity incurred by patients varies depending on the agent and the dose used and may result in treatment discontinuation. There are no studies assessing effectiveness of 5% lidocaine patch in the treatment of chemotherapy-Although induced peripheral neuropathy. mechanisms of damage differ, 5% lidocaine patch has effectively reduced symptoms and improved quality of life in patients with post herpetic neuralgia³.



Lignocaine patch (5%) for chemotherapy induced peripheral neuropathy

doi:10.1177/0192623319861937

02. AIM

To evaluate the efficacy of 5% Lignocaine patch for management of CIPN.

03. METHODOLOGY

Here, we describe application of 5% Lidocaine patches to the sole lower extremities in a patient with grade 3 CIPN subsequent to treatment with vincristine for Immediate Risk B cell Acute Lymphoblastic Leukemia. The patient was having severe tingling, numbness along with allodynia to touch (especially to cloth). He was started on tablet morphine immediate release 10mg q4hourly plus 10mg sos q1hrly along with cap. Gabapentin 300mg at night. After three days his gabapentin was increased to 300mgs bd. The patent allodynia wasn't reduced. Thus it was decided to apply lignocaine 5% for allodynia (fig.1). The treatment continued for two weeks. By the end of two weeks without any change in medications, CIPN grade 1, with allodynia was greatly reduced to symptoms, corresponding improvement in quality of life.

04. RESULTS

5% lidocaine patch application was associated with almost complete resolution of the allodynia, tingling and numbness and pain of CIPN in this patient. Concurrently decreased allodynia improved bearing his weight on the foot and allowing him to walk.



Lignocaine 5% is a promising modality of treatment for chemotherapy induced peripheral neuropathy, where allodynia is a major presenting symptom.

Windebank A, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13:27–46. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010;6(12):657–666. doi:10.1038/nrneurol.2010.160 Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. Journal of multidisciplinary healthcare. 2016;9:447-454.





AFFILIATIONS

Department of Palliative Medicine, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India

05. CONCLUSION

REFERENCES: